» Articles » PMID: 35651608

Targeting Differential Roles of Tumor Necrosis Factor Receptors As a Therapeutic Strategy for Glaucoma

Abstract

Glaucoma is an irreversible sight-threatening disorder primarily due to elevated intraocular pressure (IOP), leading to retinal ganglion cell (RGC) death by apoptosis with subsequent loss of optic nerve fibers. A considerable amount of empirical evidence has shown the significant association between tumor necrosis factor cytokine (TNF; TNFα) and glaucoma; however, the exact role of TNF in glaucoma progression remains unclear. Total inhibition of TNF against its receptors can cause side effects, although this is not the case when using selective inhibitors. In addition, TNF exerts its antithetic roles stimulation of two receptors, TNF receptor I (TNFR1) and TNF receptor II (TNFR2). The pro-inflammatory responses and proapoptotic signaling pathways predominantly mediated through TNFR1, while neuroprotective and anti-apoptotic signals induced by TNFR2. In this review, we attempt to discuss the involvement of TNF receptors (TNFRs) and their signaling pathway in ocular tissues with focus on RGC and glial cells in glaucoma. This review also outlines the potential application TNFRs agonist and/or antagonists as neuroprotective strategy from a therapeutic standpoint. Taken together, a better understanding of the function of TNFRs may lead to the development of a treatment for glaucoma.

Citing Articles

Identification of Optic Nerve-Related Biomarkers in Primary Open-Angle Glaucoma Based on Comprehensive Bioinformatics and Mendelian Randomization.

Zhao S, Dai Q, Rao Z, Li J, Wang A, Gao Z Transl Vis Sci Technol. 2024; 13(8):21.

PMID: 39133496 PMC: 11323985. DOI: 10.1167/tvst.13.8.21.


Eye Drop with Fas-Blocking Peptide Attenuates Age-Related Macular Degeneration.

Yi Y, Pyun S, Kim C, Yun G, Kang E, Heo S Cells. 2024; 13(6.

PMID: 38534392 PMC: 10969560. DOI: 10.3390/cells13060548.


Effects of different alkylating agents on photoreceptor degeneration and proliferative response of Müller glia.

Nomura-Komoike K, Nishino R, Fujieda H Sci Rep. 2024; 14(1):61.

PMID: 38167441 PMC: 10762013. DOI: 10.1038/s41598-023-50485-7.


Fluoxetine Protects Retinal Ischemic Damage in Mice.

Romano G, Gozzo L, Maurel O, Di Martino S, Riolo V, Micale V Pharmaceutics. 2023; 15(5).

PMID: 37242611 PMC: 10223683. DOI: 10.3390/pharmaceutics15051370.


Factors Associated with Elevated Tumor Necrosis Factor-α in Aqueous Humor of Patients with Open-Angle Glaucoma.

Jung Y, Ohn K, Shin H, Oh S, Park C, Park H J Clin Med. 2022; 11(17).

PMID: 36079162 PMC: 9457301. DOI: 10.3390/jcm11175232.

References
1.
Jeucken K, Kaaij M, Rip J, van Rooijen C, Kan Y, Corneth O . Splenic Architecture and Function Requires Tight Control of Transmembrane TNF Expression. Int J Mol Sci. 2022; 23(4). PMC: 8876982. DOI: 10.3390/ijms23042229. View

2.
Clark I, Vissel B . Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective - a Commentary. Expert Rev Neurother. 2019; 19(6):535-543. DOI: 10.1080/14737175.2019.1618710. View

3.
Antoni C, Braun J . Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol. 2002; 20(6 Suppl 28):S152-7. View

4.
Yang X, Yu X, Zhang D, Fan Z . Blood-retinal barrier as a converging pivot in understanding the initiation and development of retinal diseases. Chin Med J (Engl). 2020; 133(21):2586-2594. PMC: 7722606. DOI: 10.1097/CM9.0000000000001015. View

5.
Kondkar A, Azad T, Almobarak F, Kalantan H, Al-Obeidan S, Abu-Amero K . Elevated levels of plasma tumor necrosis factor alpha in patients with pseudoexfoliation glaucoma. Clin Ophthalmol. 2018; 12:153-159. PMC: 5775737. DOI: 10.2147/OPTH.S155168. View